Tremfya Shows Head-To-Head Edge Versus Stelara In Crohn’s

Johnson & Johnson tested Tremfya against its established Stelara as the “benchmark” in IBD. Tremfya, already up for approval in ulcerative colitis, is planned for filing in Crohn’s later in 2024.